Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark C. Hurley who wrote (560)	2/16/1998 9:48:00 AM
From: Wesley0428	Read Replies (1) of 849

<<<I am new to this site, but not new to Matritech. I read through these folders and there was pretty good information in here.>>> Welcome. Maybe you should read these folders more closely. <<< I agree with John that the colorectal cancer product that is in Phase I of FDA clinical trials (4 months now) is the big money maker for this stock.>>> It's awaiting FDA 510k approval, which would be considered the final approval stage in this case. <<<But noone should cross off the NMP22 test kit. It is still the best prostate cancer screening test around>>> NMP22 is a bladder cancer test <<<I read posts from a while ago with concern over Bayer backing out on Matritech's colorectal test.>>> Bayer's deal is to automate a cervical cancer test <<<Don't forget that Bayer has made a large contribution in money to Matritech.>>> Bayer's financial contribution to Matritech to date is minimal

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next